Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 06, 2017 09:00 ET
|
Rexahn Pharmaceuticals
Presented Preliminary Clinical Efficacy Data on RX-3117 in Bladder Cancer and Final Data on the Supinoxin™ Phase I Study at the ESMO Congress Strengthened Patent Position on RX-3117 and Supinoxin™ ...
Rexahn Announces $8 Million Registered Direct Offering
October 13, 2017 08:59 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN) today announced it has entered into definitive agreements with institutional investors to purchase...
Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117
October 10, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE AMERICAN:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC
September 21, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE AMERICAN:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the...
Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress
September 11, 2017 08:15 ET
|
Rexahn Pharmaceuticals
Supinoxin™ is well tolerated and shows preliminary evidence of clinical activity in difficult to treat tumors Preclinical studies on RX-3117 demonstrate additive and synergistic effects with...
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology (ESMO) Congress
September 10, 2017 08:15 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Sept. 10, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Pharmaceuticals to Present at 19th Annual Rodman & Renshaw Global Investment Conference
September 06, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of...
Rexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical Oncology (ESMO) Congress
September 05, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors
September 01, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™
August 30, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...